Chair, Percheron Therapeutics
| Role | Organisation | Sources |
|---|---|---|
| Chair | Percheron Therapeutics | Biotech Dispatch (Tue 1 Sep 2026), Biotech Dispatch (Mon 10 Aug 2026) |
| Chief Medical Officer (former) | CSL Behring | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Independent Non-Executive Director | George Medicines | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Dr Charmaine Gittleson. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Percheron Therapeutics has locked in $2.3 million through an institutional placement to fund a Vanderbilt Health trial of its HMBD-002 antibody in blood cancers.
Percheron Therapeutics has appointed Arovella Therapeutics' former leader Michael Baker as CEO from October, with James Garner departing for an overseas role while joining the board as a non-executive director.
George Medicines, a George Institute spin-out developing combination blood pressure therapies, has appointed former CSL Behring chief medical officer Dr Charmaine Gittleson as an independent non-executive director as its drug GMRx2 enters Phase III trials.
Drug developer George Medicines has added Dr Charmaine Gittleson to its board as an independent non-executive director, bringing pharma and CSL Behring leadership experience as its hypertension candidate GMRx2 advances through Phase III trials.